Gyg Share Discussion Threads

[gopher] 05/3/2003 20:52

In line results with further progress expected this year mean the company trades on a prospective pe of 16. Not exactly a bargain but a good defensive sector and Gyrus remains on my watchlist waiting for growth stocks to come back into fashion.

[doomandgloom] 05/3/2003 17:33

Great News

[boram] 04/3/2003 00:19

Gyrus Group, Finals are out on Wednesday 5th.

[doomandgloom] 20/2/2003 20:41

Great News

[maddox] 19/2/2003 23:12

Good news on yet another large potential market for Gyrus - Cosmetic Surgery...

Unveils results of trials conducted on its PlasmaKinetic(R) II (PKII) technology for use in cosmetic surgery which showed that single-blind randomised case control pilot trial on the treatment of benign skin lesions conducted in the UK, met the objectives of demonstrating the same efficacy and low complication rate as use of a Carbon Dioxide Laser. The pre-clinical study in the US concluded that PKII may have the ability to produce a significant clinical effect with a more rapid healing time compared to Carbon Dioxide Laser. This result now needs to be validated in the treatment of sun-damaged, wrinkled, facial skin, the company said. A protocol for treating sun-damaged skin has been submitted in the UK and further submissions will now also be made at key US investigator sites. "These results are very encouraging and we now need to assess whether the potential benefits of our technology are transferable to the target applications of treating the facial effects of sun-damage as well as other cosmetic blemishes", said Mark Goble, Gyrus Group Managing Director.

[dhmace] 19/2/2003 13:58

Buying activity to-day

[thumper123] 31/1/2003 23:07

Ah I see! Thanks Maddox

[maddox] 31/1/2003 22:33

thumper,

This the opportunity for Gyrus. The fact that the current laser procedure doesn't work (neighbour of mine has a similar tale - his wife confirms!). The laser surgery is pretty invasive, leaves scarring and is often unsuccessful. The Gyrus technique is no more trouble that having a filling, has no scarring, and far better results.

There have been reports that it is taking time to penetrate the market - hardly a surprise in the conservative UK market - but there is a huge latent market out there when it does break through.

Maddox

[gopher] 27/1/2003 12:26

A month away from 2002 results. Brokers forecasting eps of 8p in 2002 and 11p this year. Not expensive if growth stocks come back into fashion but dividends seem more important at the moment.

[thumper123] 27/1/2003 08:15

Know someone who had laser surgery on soft palate to cure big-time snoring problem. Problem with surgery is the tissue re-grows. Six months later snoring again. Possibly this is why limited interest in procedure. DYOR etc.

[btulloch] 23/12/2002 00:33

Encouraging article in todays Scotland on Sunday.

[ok,yah] 17/12/2002 22:49

Todays independant reports on talk of weak take-up of Gyrus's procedure aimed at tackling snoring

[rambutan2] 10/12/2002 14:05

keeps popping up amongst the shrewdies favs - are they right this time?

[maddox] 30/11/2002 14:10

Whatever. It looks like Gyrus is picking up institutional support, prehaps the buyers stike is coming to an end and new money is looking for growth stock opportunities. Gyrus is a classic growth opportunity in a defensive sector. But then again I've thought that these characteristic should be attractive all along.

When Gyrus moves it tends to be in big jumps - so if your not in or on the screen you miss it.

Regards, Maddox

[maddox] 20/11/2002 05:43

Gopher
Surely, a low p/e would indicate that Gyrus are therefore far better value than S&N?

What figures do they quote?

Regards, Maddox

[maddox] 09/11/2002 12:35

Gopher,

What would you expect? This company is a fast growing company of course it isn't throwing off cash - its going into two areas:

a) It is being invested in Generator placement; and
b) Its going into working capital.

Thr first is driving growth forward and securing market share and the second is supporting the growth that it is creating. Generators are offered to hospital units if they commit to carry out a number operations using Gyrus disposable instruments. It establishes Gyrus as the preferred tool for the surgeon and overcomes the barrier of an upfront capital expenditure by the hospital.

Regards, Maddox

[gopher] 09/11/2002 01:29

Maddox,

Collins Stewart rate this as accumulate with a prospective PE far below Smith & Nephew. Tend to agree with them and I see no hurry to buy back into a growth stock like this but it remains on my watch list.

regards
Gopher

[maddox] 28/10/2002 23:38

gopher,

Oh yes terribly difficult. Look at the figures - the existing business has got double digit growth, the new businesses have double digit growth, new products are being introduced every six months widening its scope and the margins keep widening. Real puzzler this one - not.

Maddox

[gopher] 28/10/2002 21:13

It remains difficult to get a steer on whether the group is actually creating value however they have expanded using equity rather than debt so shorters and bulls may both me wrong. My guess is they are going to profitable but whether they attain a growth reputation is another question.

[vs] 04/10/2002 18:18

Diego Powered Dissector! LOL!
A masterpiece of a name? Or very dodgy, given that Mexico shares a border with the USA!

[maddox] 04/10/2002 18:10

LONDON (AFX)1/10/02 - Gyrus Group PLC said it introduced two key products, the G2
Integrated Workstation and the Diego Powered Dissector, at the American Academy
of Otorhinolaryngology Meeting last week in San Diego.
The group, which specialises in the surgical management of tissue using less
traumatic techniques, said the G2 system is for head and neck surgery and the
Diego is a powered dissector for sinus and nasal surgery.
Gyrus said surgeons will be able to select from a combination of tissue
effects available from the G2 system when treating snoring conditions,
obstructive sleep apnoea, enlarged tonsils, nasal turbinates, adenoids and head
and neck oncology.
The group said the market for treatment of soft tissues in the head and neck
region is estimated at 1 bln usd.
[e-mail]
el/rn
NNN

[cat] 18/9/2002 14:20

trying to turn em